Medium term outcomes of transapical aortic valve implantation: Results from the Italian registry of trans-apical aortic valve implantation

Augusto D'Onofrio, Stefano Salizzoni, Marco Agrifoglio, Linda Cota, Giampaolo Luzi, Paolo M. Tartara, Giovanni D. Cresce, Marco Aiello, Carlo Savini, Mauro Cassese, Alfredo Cerillo, Giuseppe Punta, Micaela Cioni, Davide Gabbieri, Chiara Zanchettin, Andrea Agostinelli, Enzo Mazzaro, Omar Di Gregorio, Giuseppe Gatti, Giuseppe FaggianClaudia Filippini, Mauro Rinaldi, Gino Gerosa

Research output: Contribution to journalArticlepeer-review


Background: Transcatheter aortic valve implantation (TAVI) has been proposed as a therapeutic option for high-risk or inoperable patients with severe symptomatic aortic valve stenosis. The aim of this multicenter study was to assess early and medium term outcomes of transapical aortic valve implantation (TA-TAVI). Methods: From April 2008 through June 2012, a total of 774 patients were enrolled in the Italian Registry of Trans-Apical Aortic Valve Implantation (I-TA). Twenty-one centers were included in the I-TA registry. Outcomes were also analyzed according to the impact of the learning curve (first 50% cases versus second 50% cases of each center) and of the procedural volume (high-volume versus low-volume centers). Results: Mean age was 81.0 ± 6.7 years, mean logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) I, EuroSCORE II, and The Society of Thoracic Surgeons risk score were 25.6% ± 16.3%, 9.4% ± 11.0%, and 10.6% ± 8.5%, respectively. Median follow-up was 12 months (range, 1 to 44). Thirty-day mortality was 9.9% (77 patients). Overall 1-, 2-, and 3-year survival was 81.7% ± 1.5%, 76.1% ± 1.9%, and 67.6% ± 3.2%, respectively. Thirty-day mortality of the first 50% patients of each center was higher when compared with the second half (p = 0.04) but 3-year survival was not different (p = 0.64). Conversely, 30-day mortality at low-volume centers versus high-volume centers was similar (p = 0.22). At discharge, peak and mean transprosthetic gradients were 21.0 ± 10.3 mm Hg and 10.2 ± 4.1 mm Hg, respectively. These values remained stable 12 and 24 months after surgery. Conclusions: Transapical TAVI provides good results in terms of early and midterm clinical and hemodynamic outcomes. Thus it appears to be a safe and effective alternative treatment for patients who are inoperable or have high surgical risk.

Original languageEnglish
Pages (from-to)830-836
Number of pages7
JournalAnnals of Thoracic Surgery
Issue number3
Publication statusPublished - Sep 2013

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Medium term outcomes of transapical aortic valve implantation: Results from the Italian registry of trans-apical aortic valve implantation'. Together they form a unique fingerprint.

Cite this